Brief: Leap Therapeutics Announces First Patient Enrolled In Defiance Study Of Dkn-01 For The Treatment Of Colorectal Cancer Patients
17/10/2022 12:18
Oct 17 (Reuters) - Leap Therapeutics Inc LPTX.O :
* LEAP THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN
DEFIANCE
STUDY OF DKN-01 FOR THE TREATMENT OF COLORECTAL CANCER PATIENTS
Source text for Eikon: ID:nPn5DjQ14a
Further company coverage: LPTX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cypherpunk Technologies
See all newsCypherpunk Technologies Inc reports results for the quarter ended June 30 - Earnings Summary
Cypherpunk Technologies swings to Q2 profit on Zcash gains
Cypherpunk Technologies Inc expected to post a loss of 3 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia